v3.26.1
Loss per share
 6 Months Ended
Jun. 30, 2026
Loss per share  
Loss per share

4.Loss per share

​

​

​

​

​

​

​

​

For the Six Months

​

​

Ended June 30, 

In CHF thousands except for share and per share data

  ​ ​ ​

2026

​

2025

Loss per share (EPS)

​

  ​

  ​ ​ ​

  ​

Numerator

​

  ​

 

  ​

Net loss attributable to equity holders of the Company

​

(12,927)

 

(40,218)

Denominator

​

​

 

  ​

Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders

​

101,963,177

 

100,519,884

Basic and diluted loss per share for the period attributable to equity holders

​

(0.13)

 

(0.40)

​

In periods for which AC Immune has a loss, basic net loss per share is the same as diluted net loss per share. The Company has excluded from the calculation of diluted loss per share all potentially dilutive in-the-money share options. See “Note 12. Share-based compensation” for the potentially dilutive equity awards.